Education
About Us
Working with TipRanks
Follow Us
Lyra Therapeutics (LYRA)
NASDAQ:LYRA
Total Valuation
Lyra Therapeutics has a market cap or net worth of $15.02M. The enterprise value is $64.61M.
Market Cap$15.02M
Enterprise Value$64.61M
Share Statistics
Lyra Therapeutics has 1,325,344 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,325,344
Owned by Insiders3.27%
Owned by Institutions24.14%
Financial Efficiency
Lyra Therapeutics’s return on equity (ROE) is -8.06 and return on invested capital (ROIC) is -166.66%.
Return on Equity (ROE)-8.06
Return on Assets (ROA)-1.41
Return on Invested Capital (ROIC)-166.66%
Return on Capital Employed (ROCE)-1.79
Revenue Per Employee51.13K
Profits Per Employee-3.11M
Employee Count30
Asset Turnover0.02
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Lyra Therapeutics is -0.14. Lyra Therapeutics’s PEG ratio is 0.04.
PE Ratio-0.14
PS Ratio0.00
PB Ratio1.18
Price to Fair Value1.16
Price to FCF-2.18
Price to Operating Cash Flow-2.19
PEG Ratio0.04
Income Statement
In the last 12 months, Lyra Therapeutics had revenue of 1.53M and earned -93.44M in profits. Earnings per share was -71.50.
Revenue1.53M
Gross Profit1.06M
Operating Income-96.35M
Pretax Income-93.40M
Net Income-93.44M
EBITDA-60.26M
Earnings Per Share (EPS)-71.50
Cash Flow
In the last 12 months, operating cash flow was -56.40M and capital expenditures -189.00K, giving a free cash flow of -56.59M billion.
Operating Cash Flow-56.40M
Free Cash Flow-56.59M
Free Cash Flow per Share-42.70
Dividends & Yields
Lyra Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.23
52-Week Price Change-12.44%
50-Day Moving Average7.95
200-Day Moving Average10.00
Relative Strength Index (RSI)48.97
Average Volume (3m)1.34M
Important Dates
Lyra Therapeutics upcoming earnings date is Aug 12, 2025, TBA Not Confirmed.
Last Earnings DateMay 6, 2025
Next Earnings DateAug 12, 2025
Ex-Dividend Date―
Financial Position
Lyra Therapeutics as a current ratio of 3.41, with Debt / Equity ratio of 2.74%
Current Ratio3.41
Quick Ratio3.41
Debt to Market Cap2.56
Net Debt to EBITDA0.10
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Lyra Therapeutics has paid 39.00K in taxes.
Income Tax39.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Lyra Therapeutics EV to EBITDA ratio is -0.12, with an EV/FCF ratio of -0.10.
EV to Sales4.72
EV to EBITDA-0.12
EV to Free Cash Flow-0.10
EV to Operating Cash Flow-0.10
Balance Sheet
Lyra Therapeutics has $31.73M in cash and marketable securities with $33.36M in debt, giving a net cash position of $1.62M billion.
Cash & Marketable Securities$31.73M
Total Debt$33.36M
Net Cash$1.62M
Net Cash Per Share$1.22
Tangible Book Value Per Share$8.90
Margins
Gross margin is 21.72%, with operating margin of -6280.83%, and net profit margin of -6090.94%.
Gross Margin21.72%
Operating Margin-6280.83%
Pretax Margin-6088.40%
Net Profit Margin-6090.94%
EBITDA Margin-3928.42%
EBIT Margin-3959.13%
Analyst Forecast
The average price target for Lyra Therapeutics is $23.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$23.00
Price Target Upside103.00% Upside
Analyst ConsensusHold
Analyst Count3
Revenue Growth Forecast-29.46%
EPS Growth Forecast2.71%